Home » Page 21

The Monoclonal Pursuit of the Next CMV Therapeutic

Posted on by — No Comments ↓

There is no doubt that immunity to human cytomegalovirus (CMV) is both cell-and antibody-mediated. Studies in transplant patients showed that absence of T-cell protection with chemotherapy is a set-up for recurrent and severe CMV disease. It was also shown that patients with pre-existing CMV antibodies are less likely to develop CMV Continue reading The Monoclonal Pursuit of the Next CMV Therapeutic→

TXA-709 –  New Kid on the Block

Posted on by — No Comments ↓

When searching for FtsZ inhibitors on PubMed, there are 187 hits. When narrowing down the search looking for clinical trials only, there are none. Taxis Pharmaceuticals obtained QIDP status for its candidate drug TXA-709 in late 2016 and it is still in preclinical testing. The drug’s target, bacterial replication machinery Continue reading TXA-709 –  New Kid on the Block→

To Kill A Mocking Bug – of the CRKP or CRAB Variety

Posted on by — No Comments ↓

Meropenem stands out as an antibiotic to be used first in ESBL and MDR infections, given its efficacy profile and safety record (see earlier blog). It also would seem to be appropriate to use relatively high doses or prolonged infusion times – or both – to improve T>MIC for the Continue reading To Kill A Mocking Bug – of the CRKP or CRAB Variety→